

Wenru Song, MD, PhD



Dr. Song is currently VP of Immuno-Oncology Clinical Development at AstraZeneca. Previously, Dr. Song was the Head of Regional Oncology Development in Asia-Pacific at Millennium: The Takeda Oncology Company where he had led the building of Takeda's regional oncology development infrastructure and the regional clinical development plan across oncology portfolio. Prior to joining Millennium, Dr. Song was a medical director/clinical lead at Pfizer Oncology where he led a number of biologic compounds in cancer immunotherapeutics and antibody-drug conjugate programs. Before joining the pharmaceutical industry, he was an associate investigator at Baylor Institute of Immunology Research and an attending oncologist physician at Baylor Sammons Cancer Center in Dallas. He studied Medicine at Shandong University in China before coming to the US for his PhD study in Immunology. He then did a postdoctoral fellowship in cancer immunotherapy with Dr. Ron Crystal at Cornell University Medical Center, followed by medical residency training at Montefiore Medical Center/Albert Einstein College of Medicine, and clinical oncology fellowship at Stanford University where he also performed research on cancer immunotherapy with Drs. Ron Levy and Ed Engleman. Dr. Song is board-certified in medical oncology and internal medicine by the American Board of Internal Medicine.

Dr. Song has actively participated in community services and professional organizations. He is a founding board member, current Board Chair and the past-president of the Chinese American Hematologist and Oncologist Network (CAHON), former VP of Shandong University Overseas Alumni Association and a current invited founding member of Medical Education Advisory Council at Shandong University, an invited member of BayHelix, a former member of the *Ad Hoc* Committee on International Outreach of the American Society of Hematology (ASH), a current overseas member of the Executive Committee of the Chinese Society of Clinical Oncology, a member of the Industry Council and Immune Biomarker Taskforce of the Society for Immunotherapy of Cancer (SITC), a former member of Career Development Committee of the American Society of Clinical Oncology (ASCO), a former member of the NCI's Immune Response Modifier Pathway Prioritization Working Group, a member of the World Immunotherapy Council, and most recently an invited Organizing Committee member of the upcoming inaugural AACR Highlight meeting in China, a member of ASH Foundation and Development Committee and a member of the International Affairs Committee of ASCO. Dr. Song serves in the Editorial Board of *Journal of Hematology and Oncology* and *Chinese Clinical Oncology*.